NRTX-1001 administration has been well-tolerated in all individuals treated to date 4 of 5 subjects treated with the lower dose of NRTX-1001 report >50% seizure reduction 3 of 5 subjects report...
Neurona Therapeutics to Present at Stifel 2024 Virtual CNS Days
Neurona Therapeutics Announces Presentation of Updated Clinical Data
Neurona Therapeutics has gathered $120 million in what is expected to be its last private financing round to wrap up an open-label study this year and move its epilepsy cell therapy into a randomized Phase II in 2025, CEO and co-founder Cory Nicholas told Endpoints News.
Almost a year ago to the day, Neurona Therapeutics was cutting staff, citing a difficult funding environment. Fast forward to today, and the company has reeled in a much-needed $120 million. But according to CEO Cory Nicholas, Ph.D., you definitely should not call this a comeback.
Neurona Therapuetics presentation at upcoming Oppenheimer 34th Annual Healthcare Lifesciences Conference
Neurona Therapeutics presents new positive clinical data from 1st cohort in Ph I/II Trial of NRTX-1001 for drug reistant focal epilepsy at AES meeting
First cohort treated in Ph I/II clinical trial of NRTX-1001 in adults with focal epilepsy, update on first patients'progress
Neurona Therapeutics CEO to participate in October Investor Conferences
Publication of preclinical studies supporting ongoing open-label first-in-human Phase I/II trial of cell therapy for drug-resistant focal epilepsy